Active, not recruitingNot applicableNCT05891847
Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia
Studying Neurofibroma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Enrollment
- 150 enrolled
- Eligibility
- 3-18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (5)
- Research Site, Moscow, Moscow, Russia
- Research Site, Moscow, Russia
- Research Site, Novosibirsk, Russia
- Research Site, Saint Petersburg, Russia
- Research Site, Yekaterinburg, Russia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05891847 on ClinicalTrials.govOther trials for Neurofibroma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT06175637Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNsAstraZeneca
- RECRUITINGNANCT05199376Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1Centre Leon Berard
- ACTIVE NOT RECRUITINGPHASE2NCT03962543MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasSpringWorks Therapeutics, Inc.
- RECRUITINGPHASE1NCT02390752Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...National Cancer Institute (NCI)